How Are Responsibilities Divided for a Medical Device Registration Authorized Representative in South Korea?

Answer: Responsibilities for a South Korean medical device registration authorized representative should be divided according to the product's risk class, applicable regulatory pathway, applicant and registration holder, certificate ownership and control, regulatory communication, importation coordination, change control, renewal, and post-market obligations. Before filing, companies should confirm the target market, product risk level, applicable regulatory route, and existing documentation basis, then assess technical files, quality system evidence, labels and instructions for use, local agent or authorized representative arrangements, clinical evidence, and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission to avoid prolonged project timelines caused by unclear classification, missing records, or ambiguous authorization arrangements.

Published: 2026-07-15 17:03 | Updated: 2026-07-15 17:03

This FAQ addresses priority questions that companies must judge in actual international medical device registration projects, including documentation preparation, compliance pathways, and post-market maintenance.

Key Summary

For the question of how responsibilities are divided for a South Korean medical device registration authorized representative, companies should first confirm the target country, product risk class, applicable regulatory pathway, and existing documentation basis, then assess technical files, quality system, labels and instructions for use, local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends conducting a documentation gap assessment before formal submission to avoid lengthening the project cycle due to unclear classification, documentation, or authorization arrangements. For Chinese medical device manufacturers, a more reliable approach is to first conduct product classification and a documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused.

Target-market registration usually affects technical files, authorized representative, importer cooperation, label language, quality system evidence, and subsequent change maintenance at the same time. If a project is advanced only by asking which documents must be submitted, correction requests or rework can easily arise in model coverage, evidence chain consistency, labeling claims, and certificate control. AIMEILI recommends that companies place this question within a unified GHWP member economy and multi-country market access strategy, using one reusable core technical file set to support localization in different markets rather than recreating documentation on an ad hoc basis for each country.

Applicable Scenarios and Core Questions

Companies searching for how responsibilities are divided for a South Korean medical device registration authorized representative usually want to solve more than a conceptual question. They need to judge whether existing documentation can support target-market filing, whether a local agent or authorized representative is required, why timelines may be prolonged, and which issues may affect launch plans. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities at the same time.

If a company plans to enter multiple GHWP member economies or markets in Southeast Asia, the Middle East, and Latin America at the same time, answering the process for only one country is not enough. A more valuable approach is to first make core technical files, quality system evidence, performance verification, clinical evidence, and labels and instructions for use into reusable versions, then localize them according to each country's regulatory requirements.

Registration Judgment Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, method of body contact, duration of use, sterility, whether it is powered, and whether it contains software or IVD attributes, then determine the risk class and filing pathway. Once the pathway judgment is wrong, subsequent translation, notarization, authorization, testing, and supplementary documentation will deviate from the correct direction.

For a target-market project, it is also necessary to confirm the applicant and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market incidents, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely only in a commercial contract, they can easily affect market control rights later.

Documents and Evidence

Common documents include product description, model and specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality system evidence, technical files, performance verification reports, risk management files, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, existing registration certificates, manufacturer's declaration, and post-market surveillance materials.

The key to documentation quality is not quantity but consistency. Instructions for use claims, models covered by test reports, clinical evidence scope, risk management conclusions, label warnings, and registration application form information must support each other. Regulatory authorities focus on whether the product is safe, effective, and traceable for the intended use, not on whether the company has uploaded many documents.

Common Errors

The most common problem is treating a registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting directly translated NMPA documentation without rearranging the evidence according to the target-market pathway.
• Having too many models and specifications while test reports, clinical evidence, or labels do not provide sufficient coverage.
• Selecting a local agent only based on sales cooperation without clarifying regulatory responsibilities, certificate control rights, and post-market maintenance responsibilities.
• Inconsistency among labels, instructions for use, promotional materials, and registration documentation claims, leading to correction requests or post-market compliance risks.
• Failing to plan multi-country documentation reuse in advance, resulting in repeated preparation for each country and amplified cost and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation basis and avoid discovering key evidence gaps only after filing.

• Organize the target product list, model and specification matrix, and intended use statement.
• Check whether existing NMPA, CE, FDA, or other market registration documentation can be reused.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English instructions for use.
• Confirm the local agent or authorized representative's responsibilities, fees, certificate control rights, and exit mechanism.
• Establish a target-country gap assessment table specifying what needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI View

AIMEILI recommends that companies not understand target-market registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, first establishing a clear core technical file set and evidence matrix, then converting it according to national requirements, is usually faster, more stable, and more conducive to subsequent changes and renewals than filling documentation gaps country by country at short notice.

From a project management perspective, companies should control three things in advance: first, product classification and pathway judgment; second, consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documentation appears extensive, the project may still encounter repeated issues during correction requests, agent communication, and post-market maintenance.

Common Follow-up Questions

Can domestic documentation be used directly for target-market registration?

Domestic documentation can serve as a basis but usually cannot be submitted as is. Companies need to adjust the documentation structure, language, labels, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

A local agent usually participates in registration communication, changes, renewals, and post-market incident handling. If rights and responsibilities are unclear, certificate control rights and subsequent market stability may be affected.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project ledger that manages the product list, model and specifications, registration pathway, document owners, translation status, testing status, local agent communication records, and expected submission dates in the same table. This helps identify documentation gaps in a timely manner and helps management judge whether the project will affect launch plans.

For companies with existing registration bases in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. In particular, labels and instructions for use, clinical evaluation, risk management, performance verification, and quality system certificates must maintain consistent versions.

• Confirm the target market and product list.
• Complete risk classification and pathway judgment.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control rights.
• Track translation, notarization, testing, and correction status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulatory authorities usually examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards, and technical files are consistent. If the ISO 13485 certificate coverage does not match the filed product, or if the manufacturing address, model and specifications, or instructions for use version are inconsistent with test reports, the company may be required to provide supplementary explanations even if it has prepared many documents.

Companies should establish an evidence consistency checklist before filing, mapping the product name, model and specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and instructions for use version, and quality system certificate item by item. This action appears basic but can significantly reduce the probability of correction requests, especially for projects filed simultaneously in multiple GHWP member economies or with multiple product families.

Localization Conversion and Agent Responsibilities

Target-market registration projects usually involve arrangements for a local agent, authorized representative, importer, or registration holder. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also undertakes regulatory communication, certificate maintenance, post-market incident reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control rights and subsequent market stability.

Labels, instructions for use, and authorization documents cannot simply be translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documentation, the focus of localization conversion is to transform reusable evidence into a filing structure acceptable to the target country, rather than writing an isolated set of documentation from scratch.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is finished. Companies also need to maintain certificate validity periods, change records, distributor authorizations, complaint handling, adverse event reporting, recall processes, label versions, and regulatory update records. Many companies invest substantial effort in obtaining certification but neglect post-market maintenance. Later, once a manufacturing address change, model expansion, instructions for use update, or agent replacement occurs, the certificate may easily become disconnected from market sales.

AIMEILI recommends that companies incorporate this question into annual international registration plan management: first clarify target-market priorities, then establish reusable documentation packages and country gap lists, and finally arrange submission, correction, post-market maintenance, and renewal milestones. The value is not only improving registration efficiency in a single country, but more importantly enabling companies to form replicable overseas compliance capability and reduce the cost of starting documentation from zero each time they enter a new market.

This article is compiled based on the AIMEILI regulatory practice question bank, the medical device international registration knowledge base, and public regulatory information. Specific projects should be subject to the latest requirements of the target country's regulatory authority and the product documentation basis.

Continue Reading

• Previous: How Should a Local Agent for Medical Device Registration in South Korea Be Selected?
• Next: Why Is the Medical Device Registration Cycle in South Korea Prolonged?
• Recommended Reading: How Should a Local Agent for Medical Device Registration in Brazil Be Selected?
• Recommended Reading: How Are Responsibilities Divided for an Authorized Representative for Medical Device Registration in Brazil?
• Recommended Reading: Why Is the Medical Device Registration Cycle in Brazil Prolonged?
• Recommended Reading: What Are Common Reasons for Documentation Correction Requests in Brazil Medical Device Registration?
• Recommended Reading: How Is Post-Market Surveillance Conducted for Medical Device Registration in Brazil?
• Recommended Reading: When Must Registration Changes Be Filed for Medical Device Registration in Brazil?
• Return to FAQ Center
• News
• Contact AIMEILI

Content Review and Scope

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principles: Prioritize official regulatory authorities, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as supporting judgment.

Scope: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal advice.